1
|
Shimizu S, Nakayama M, Nguyen CT, Ishigaki H, Kitagawa Y, Yasui F, Yagi Y, Kusayanagi T, Kohara M, Itoh Y, Tojima I, Kouzaki H, Shimizu T. SARS-CoV-2 induces inflammation and intracranial infection through the olfactory epithelium-olfactory bulb pathway in non-human primates. J Neuroimmunol 2024; 387:578288. [PMID: 38237527 DOI: 10.1016/j.jneuroim.2024.578288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2023] [Revised: 12/17/2023] [Accepted: 01/06/2024] [Indexed: 02/12/2024]
Abstract
We examined the histopathological changes in the olfactory mucosa of cynomolgus and rhesus macaque models of SARS-CoV-2 infection. SARS-CoV-2 infection induced severe inflammatory changes in the olfactory mucosa. A major histocompatibility complex (MHC) class II molecule, HLA-DR was expressed in macrophage and supporting cells, and melanocytes were increased in olfactory mucosa. Supporting cells and olfactory neurons were infected, and SARS-CoV-2 N protein was detected in the axons of olfactory neurons and in olfactory bulbs. Viral RNA was detected in olfactory bulbs and brain tissues. The olfactory epithelium-olfactory bulb pathway may be important as a route for intracranial infection by SARS-CoV-2.
Collapse
Affiliation(s)
- Shino Shimizu
- Department of Otorhinolaryngology-Head and Neck Surgery, Shiga University of Medical Science, Otsu, Shiga, Japan.
| | - Misako Nakayama
- Division of Pathogenesis and Disease Regulation, Department of Pathology, Shiga University of Medical Science, Otsu, Japan
| | - Cong Thanh Nguyen
- Division of Pathogenesis and Disease Regulation, Department of Pathology, Shiga University of Medical Science, Otsu, Japan
| | - Hirohito Ishigaki
- Division of Pathogenesis and Disease Regulation, Department of Pathology, Shiga University of Medical Science, Otsu, Japan
| | - Yoshinori Kitagawa
- Division of Microbiology and Infectious Disease, Department of Pathology, Shiga University of Medical Science, Otsu, Japan
| | - Fumihiko Yasui
- Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
| | | | | | - Michinori Kohara
- Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
| | - Yasushi Itoh
- Division of Pathogenesis and Disease Regulation, Department of Pathology, Shiga University of Medical Science, Otsu, Japan
| | - Ichiro Tojima
- Department of Otorhinolaryngology-Head and Neck Surgery, Shiga University of Medical Science, Otsu, Shiga, Japan
| | - Hideaki Kouzaki
- Department of Otorhinolaryngology-Head and Neck Surgery, Shiga University of Medical Science, Otsu, Shiga, Japan
| | - Takeshi Shimizu
- Department of Otorhinolaryngology-Head and Neck Surgery, Shiga University of Medical Science, Otsu, Shiga, Japan
| |
Collapse
|
2
|
Kamisuki S, Himeno N, Tsurukawa Y, Kusayanagi T, Takeno M, Kamakura T, Kuramochi K, Sugawara F. Identification of proteins that bind to the neuroprotective agent neoechinulin A. Biosci Biotechnol Biochem 2018; 82:442-448. [PMID: 29447077 DOI: 10.1080/09168451.2018.1433018] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Neoechinulin A is an indole alkaloid with several biological activities. We previously reported that this compound protects neuronal PC12 cells from cytotoxicity induced by the peroxynitrite generator 3-morpholinosydnonimine (SIN-1), but the target proteins and precise mechanism of action of neoechinulin A were unclear. Here, we employed a phage display screen to identify proteins that bind directly with neoechinulin A. Our findings identified two proteins, chromogranin B and glutaredoxin 3, as candidate target binding partners for the alkaloid. QCM analyses revealed that neoechinulin A displays high affinity for both chromogranin B and glutaredoxin 3. RNA interference-mediated depletion of chromogranin B decreased the sensitivity of PC12 cells against SIN-1. Our results suggested chromogranin B is a plausible target of neoechinulin A.
Collapse
Affiliation(s)
- Shinji Kamisuki
- a School of Veterinary Medicine , Azabu University , Kanagawa , Japan
| | - Natsumi Himeno
- b Department of Applied Biological Science , Tokyo University of Science , Chiba , Japan
| | - Yukine Tsurukawa
- a School of Veterinary Medicine , Azabu University , Kanagawa , Japan
| | - Tomoe Kusayanagi
- b Department of Applied Biological Science , Tokyo University of Science , Chiba , Japan
| | - Masahiro Takeno
- b Department of Applied Biological Science , Tokyo University of Science , Chiba , Japan
| | - Takashi Kamakura
- b Department of Applied Biological Science , Tokyo University of Science , Chiba , Japan
| | - Kouji Kuramochi
- b Department of Applied Biological Science , Tokyo University of Science , Chiba , Japan
| | - Fumio Sugawara
- b Department of Applied Biological Science , Tokyo University of Science , Chiba , Japan
| |
Collapse
|
3
|
Izaguirre-Carbonell J, Kawakubo H, Murata H, Tanabe A, Takeuchi T, Kusayanagi T, Tsukuda S, Hirakawa T, Iwabata K, Kanai Y, Ohta K, Miura M, Sakaguchi K, Matsunaga S, Sahara H, Kamisuki S, Sugawara F. Novel anticancer agent, SQAP, binds to focal adhesion kinase and modulates its activity. Sci Rep 2015; 5:15136. [PMID: 26456697 PMCID: PMC4601023 DOI: 10.1038/srep15136] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2015] [Accepted: 09/18/2015] [Indexed: 01/03/2023] Open
Abstract
SQAP is a novel and promising anticancer agent that was obtained by structural modifications from a natural compound. SQAP inhibits angiogenesis in vivo resulting in increased hypoxia and reduced tumor volume. In this study, the mechanism by which SQAP modifies the tumor microenvironment was revealed through the application of a T7 phage display screening. This approach identified five SQAP-binding proteins including sterol carrier protein 2, multifunctional enzyme type 2, proteasomal ubiquitin receptor, UV excision repair protein and focal adhesion kinase (FAK). All the interactions were confirmed by surface plasmon resonance analysis. Since FAK plays an important role in cell turnover and angiogenesis, the influence of SQAP on FAK was the principal goal of this study. SQAP decreased FAK phosphorylation and cell migration in human umbilical vein endothelial cells and A549 cancer cells. These findings suggest that inhibition of FAK phosphorylation works as the mechanism for the anti-angiogenesis activity of SQAP.
Collapse
Affiliation(s)
- Jesus Izaguirre-Carbonell
- Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Hirofumi Kawakubo
- Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Hiroshi Murata
- Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Atsushi Tanabe
- Laboratory of Biology, Azabu University School of Veterinary Medicine, Sagamihara 229-8501, Japan
| | - Toshifumi Takeuchi
- Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Tomoe Kusayanagi
- Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Senko Tsukuda
- Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Takeshi Hirakawa
- Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Kazuki Iwabata
- Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Yoshihiro Kanai
- Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Keisuke Ohta
- Department of Oral Radiation Oncology, Graduate school, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-85-10, Japan
| | - Masahiko Miura
- Department of Oral Radiation Oncology, Graduate school, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-85-10, Japan
| | - Kengo Sakaguchi
- Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Sachihiro Matsunaga
- Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Hiroeki Sahara
- Laboratory of Biology, Azabu University School of Veterinary Medicine, Sagamihara 229-8501, Japan
| | - Shinji Kamisuki
- Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Fumio Sugawara
- Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| |
Collapse
|
4
|
Shishido T, Hachisuka M, Ryuzaki K, Miura Y, Tanabe A, Tamura Y, Kusayanagi T, Takeuchi T, Kamisuki S, Sugawara F, Sahara H. EpsinR, a target for pyrenocine B, role in endogenous MHC-II-restricted antigen presentation. Eur J Immunol 2014; 44:3220-31. [DOI: 10.1002/eji.201444475] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2014] [Revised: 07/31/2014] [Accepted: 09/03/2014] [Indexed: 01/28/2023]
Affiliation(s)
- Tatsuya Shishido
- Laboratory of Biology; Azabu University School of Veterinary Medicine; Sagamihara Japan
| | - Masami Hachisuka
- Laboratory of Biology; Azabu University School of Veterinary Medicine; Sagamihara Japan
| | - Kai Ryuzaki
- Laboratory of Biology; Azabu University School of Veterinary Medicine; Sagamihara Japan
| | - Yuko Miura
- Laboratory of Biology; Azabu University School of Veterinary Medicine; Sagamihara Japan
| | - Atsushi Tanabe
- Laboratory of Biology; Azabu University School of Veterinary Medicine; Sagamihara Japan
| | - Yasuaki Tamura
- Department of Pathology; Sapporo Medical University School of Medicine; Sapporo Japan
| | - Tomoe Kusayanagi
- Genome and Drug Research Center; Tokyo University of Science; Chiba Japan
| | - Toshifumi Takeuchi
- Genome and Drug Research Center; Tokyo University of Science; Chiba Japan
| | - Shinji Kamisuki
- Genome and Drug Research Center; Tokyo University of Science; Chiba Japan
| | - Fumio Sugawara
- Genome and Drug Research Center; Tokyo University of Science; Chiba Japan
| | - Hiroeki Sahara
- Laboratory of Biology; Azabu University School of Veterinary Medicine; Sagamihara Japan
| |
Collapse
|
5
|
Takakusagi Y, Manita D, Kusayanagi T, Izaguirre-Carbonell J, Takakusagi K, Kuramochi K, Iwabata K, Kanai Y, Sakaguchi K, Sugawara F. Mapping a disordered portion of the Brz2001-binding site on a plant monooxygenase, DWARF4, using a quartz-crystal microbalance biosensor-based T7 phage display. Assay Drug Dev Technol 2013; 11:206-15. [PMID: 23514038 DOI: 10.1089/adt.2012.478] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
In small-molecule/protein interaction studies, technical difficulties such as low solubility of small molecules or low abundance of protein samples often restrict the progress of research. Here, we describe a quartz-crystal microbalance (QCM) biosensor-based T7 phage display in combination use with a receptor-ligand contacts (RELIC) bioinformatics server for application in a plant Brz2001/DWARF4 system. Brz2001 is a brassinosteroid biosynthesis inhibitor in the less-soluble triazole series of compounds that targets DWARF4, a cytochrome P450 (Cyp450) monooxygenase containing heme and iron. Using a Brz2001 derivative that has higher solubility in 70% EtOH and forms a self-assembled monolayer on gold electrode, we selected 34 Brz2001-recognizing peptides from a 15-mer T7 phage-displayed random peptide library using a total of four sets of one-cycle biopanning. The RELIC/MOTIF program revealed continuous and discontinuous short motifs conserved within the 34 Brz2001-selected 15-mer peptide sequences, indicating the increase of information content for Brz2001 recognition. Furthermore, an analysis of similarity between the 34 peptides and the amino-acid sequence of DWARF4 using the RELIC/MATCH program generated a similarity plot and a cluster diagram of the amino-acid sequence. Both of these data highlighted an internally located disordered portion of a catalytic site on DWARF4, indicating that this portion is essential for Brz2001 recognition. A similar trend was also noted by an analysis using another 26 Brz2001-selected peptides, and not observed using the 27 gold electrode-recognizing control peptides, demonstrating the reproducibility and specificity of this method. Thus, this affinity-based strategy enables high-throughput detection of the small-molecule-recognizing portion on the target protein, which overcomes technical difficulties such as sample solubility or preparation that occur when conventional methods are used.
Collapse
Affiliation(s)
- Yoichi Takakusagi
- Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, Chiba 278-8510, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Kusayanagi T, Tsukuda S, Shimura S, Manita D, Iwakiri K, Kamisuki S, Takakusagi Y, Takeuchi T, Kuramochi K, Nakazaki A, Sakaguchi K, Kobayashi S, Sugawara F. The antitumor agent doxorubicin binds to Fanconi anemia group F protein. Bioorg Med Chem 2012; 20:6248-55. [DOI: 10.1016/j.bmc.2012.09.015] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2012] [Revised: 09/06/2012] [Accepted: 09/07/2012] [Indexed: 12/30/2022]
|
7
|
Tsukuda S, Kusayanagi T, Umeda E, Watanabe C, Tosaki YT, Kamisuki S, Takeuchi T, Takakusagi Y, Shiina I, Sugawara F. Ridaifen B, a tamoxifen derivative, directly binds to Grb10 interacting GYF protein 2. Bioorg Med Chem 2012. [PMID: 23199482 DOI: 10.1016/j.bmc.2012.10.037] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Ridaifen B (RID-B) is a tamoxifen derivative that potently inhibits breast tumor growth. RID-B was reported to show anti-proliferating activity for a variety of estrogen receptor (ER)-positive human cancer cells. Interestingly, RID-B was also reported to possess higher potency than that of tamoxifen even for some ER-negative cells, suggesting an ER-independent mechanism of action. In this study, a T7 phage display screen and subsequent binding analyses have identified Grb10 interacting GYF protein 2 (GIGYF2) as a RID-B-binding protein. Using a cell-based assay, the Akt phosphorylation level mediated by GIGYF2 was found to have decreased in the presence of RID-B.
Collapse
Affiliation(s)
- Senko Tsukuda
- Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Matsumoto Y, Shindo Y, Takakusagi Y, Takakusagi K, Tsukuda S, Kusayanagi T, Sato H, Kawabe T, Sugawara F, Sakaguchi K. Screening of a library of T7 phage-displayed peptides identifies alphaC helix in 14-3-3 protein as a CBP501-binding site. Bioorg Med Chem 2011; 19:7049-56. [PMID: 22032894 DOI: 10.1016/j.bmc.2011.10.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2011] [Accepted: 10/04/2011] [Indexed: 01/01/2023]
Abstract
CBP501 is a chemically modified peptide composed of twelve unnatural d-amino acids, which inhibits Chk kinase and abrogates G2 arrest induced by DNA-damaging agents. Here we identified an alphaC helix in 14-3-3 protein as a CBP501-binding site using T7 phage display technology. An affinity selection of T7 phage-displayed peptide using biotinylated CBP501 identified a 14-mer peptide NSDCIISRKIEQKE. This peptide sequence showed similarity to a portion of the alphaC helix of human 14-3-3ε, suggesting that CBP501 may bind to this region. Surface plasmon resonance (SPR) and ELISA demonstrated that CBP501 interacts with 14-3-3ε specifically at the screen-guided region. An avidin-agarose bead pull-down assay showed that CBP501 also binds to other 14-3-3 isoforms in Jurkat cells. Among the other known Chk kinase inhibitors tested, CBP501 showed the strongest affinity for 14-3-3ε. Thus, we conclude that in addition to the direct inhibition of Chk kinase activity, CBP501 directly binds to cellular 14-3-3 proteins through alphaC helix.
Collapse
Affiliation(s)
- Yuki Matsumoto
- Department of Applied Biological Sciences, Faculty of Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Manita D, Toba Y, Takakusagi Y, Matsumoto Y, Kusayanagi T, Takakusagi K, Tsukuda S, Takada K, Kanai Y, Kamisuki S, Sakaguchi K, Sugawara F. Camptothecin (CPT) directly binds to human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and inhibits the hnRNP A1/topoisomerase I interaction. Bioorg Med Chem 2011; 19:7690-7. [PMID: 22071521 DOI: 10.1016/j.bmc.2011.09.059] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2011] [Accepted: 09/29/2011] [Indexed: 12/20/2022]
Abstract
Camptothecin (CPT) is an anti-tumor natural product that forms a ternary complex with topoisomerase I (top I) and DNA (CPT-top I-DNA). In this study, we identified the direct interaction between CPT and human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) using the T7 phage display technology. On an avidin-agarose bead pull down assay, hnRNP A1 protein was selectively pulled down in the presence of C20-biotinylated CPT derivative (CPT-20-B) both in vitro and in vivo. The interaction was also confirmed by an analysis on a quartz-crystal microbalance (QCM) device, yielding a K(D) value of 82.7 nM. A surface plasmon resonance (SPR) analysis revealed that CPT inhibits the binding of hnRNP A1 to top I (K(D): 260 nM) in a non-competitive manner. Moreover, an in vivo drug evaluation assay using Drosophila melanogaster showed that the knockout of the hnRNP A1 homolog Hrb87F gene showed high susceptibility against 5-50 μM of CPT as compared to a wild-type strain. Such susceptibility was specific for CPT and not observed after treatment with other cytotoxic drugs. Collectively, our data suggests that CPT directly binds to hnRNP A1 and non-competitively inhibits the hnRNP A1/top I interaction in vivo. The knockout strain loses the hnRNP A1 homolog as a both CPT-binding partner and naïve brakes of top I, which enhances the formation of the CPT-top I-DNA ternary complexes and subsequently sensitizes the growth inhibitory effect of CPT in D. melanogaster.
Collapse
Affiliation(s)
- Daisuke Manita
- Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Takakusagi Y, Takakusagi K, Ida N, Takami M, Matsumoto Y, Kusayanagi T, Nakabayashi T, Aoki S, Murata H, Ohta K, Sugawara F, Sakaguchi K. Binding region and interaction properties of sulfoquinovosylacylglycerol (SQAG) with human vascular endothelial growth factor 165 revealed by biosensor-based assays. Med Chem Commun 2011. [DOI: 10.1039/c1md00180a] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
11
|
Takeuchi T, Takahashi N, Ishi K, Kusayanagi T, Kuramochi K, Sugawara F. Antitumor antibiotic fostriecin covalently binds to cysteine-269 residue of protein phosphatase 2A catalytic subunit in mammalian cells. Bioorg Med Chem 2009; 17:8113-22. [PMID: 19857968 DOI: 10.1016/j.bmc.2009.09.050] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2009] [Revised: 09/25/2009] [Accepted: 09/26/2009] [Indexed: 11/25/2022]
Abstract
Fostriecin is a phosphate monoester with excellent antitumor activity against mouse leukemia, and it is a potent inhibitor of protein phosphatase (PP) 2A. This compound has been predicted to covalently bind to the Cys269 residue of the PP2A catalytic subunit (PP2Ac) at the alpha,beta-unsaturated lactone via a conjugate addition reaction. However, this binding has not yet been experimentally proven. To confirm such binding, we synthesized biotin-labeled fostriecin (bio-Fos), which has an inhibitory activity against the proliferation of mouse leukemia cells. We showed that fostriecin directly binds to PP2Ac in HeLa S3 cells by pull-down assays using bio-Fos. Moreover, we directly demonstrated that fostriecin covalently binds to the Cys269 residue of PP2Ac by matrix assisted laser desorption/ionization time-of-flight mass spectrometry analysis. From these results, the inhibitory mechanism of fostriecin on PP2A activity is discussed.
Collapse
Affiliation(s)
- Toshifumi Takeuchi
- Department of Applied Biological Science, Tokyo University of Science (RIKADAI), 2641 Yamazaki, Noda-shi, Chiba 278-8510, Japan
| | | | | | | | | | | |
Collapse
|
12
|
Takakusagi Y, Kuramochi K, Takagi M, Kusayanagi T, Manita D, Ozawa H, Iwakiri K, Takakusagi K, Miyano Y, Nakazaki A, Kobayashi S, Sugawara F, Sakaguchi K. Efficient one-cycle affinity selection of binding proteins or peptides specific for a small-molecule using a T7 phage display pool. Bioorg Med Chem 2008; 16:9837-46. [DOI: 10.1016/j.bmc.2008.09.061] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2008] [Revised: 09/19/2008] [Accepted: 09/20/2008] [Indexed: 10/21/2022]
|
13
|
Kusayanagi T. [Studies on urinary C-peptide excretion in normal children and children with insulin-dependent diabetes mellitus]. Nihon Ika Daigaku Zasshi 1989; 56:103-22. [PMID: 2659621 DOI: 10.1272/jnms1923.56.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
In 115 normal children (3 to 14 years old) and 143 children with insulin-dependent diabetes mellitus (6 to 15 years old), the urinary C-peptide immunoreactivity) was measured for evaluation of the pancreatic B cell function. The urinary C-peptide excretions during O-GTT corresponded to the change of serum C-peptide levels in normal children (n = 27) and the mean value of the excretions in younger children was significantly low. Age did not significantly affect basal serum C-peptide levels (ng/ml) and urinary C-peptide excretions (micrograms/h) before O-GTT, but significant differences in serum sigma C-peptide (ng/ml) and urinary C-peptide (micrograms/3 h) during O-GTT were noted between the younger group and the older group (p less than 0.01). In 39 normal children on an inactive routine, mean values of the 24 h urinary C-peptide for children aged from 3 to 6, 7 to 10 and from 11 to 14 years old, were 28.2 +/- 12.6 micrograms/day, 32.3 +/- 8.4 micrograms/day and 37.6 +/- 10.6 micrograms/day (mean +/- SD) respectively with significant differences according to age (younger group vs older group, p less than 0.05). The effects of daily routine on 24 h urinary C-peptide were studied in normal children. In children on an active routine, the C-peptide excretion was significantly less than in the same individuals on an inactive routine (26.9 +/- 9.9 micrograms/day vs 34.3 +/- 14.5 micrograms/day, p less than 0.01). In children with insulin-dependent diabetes mellitus, 24 h urinary C-peptide excretion was studied to evaluate residual pancreatic B cell function. Urinary C-peptide was measurable in 47 of the 143 diabetic children, suggesting that most of the pancreatic B cells had deteriorated in the other 96 patients. In the 96 patients without B cell function, the averages of daily dose of insulin and 24 h-U.glucose/TAG ratio were significantly higher than those in the 47 patients who had pancreatic B cell function estimated by measuring urinary C-peptide (p less than 0.001). In additional studies on the 43 diabetic children with residual pancreatic B cell function, who had had the disease for five years or less, the 24 h urinary C-peptide excretion (micrograms/day) correlated weakly but significantly with the duration of the disease (r = -0.28, p less than 0.05). Patients who had had the disease longer and who were controlled with larger doses of insulin had less of the 24 h urinary C-peptide.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
|
14
|
Motohiro T, Sakata Y, Fujimoto T, Nishiyama T, Ishimoto K, Tominaga K, Yamashita F, Onoda Y, Kusayanagi T, Tsuboi M, Toubo Y, Yamamoto M, Komatsu R, Tanaka C, Baba Y. [Laboratory and clinical studies of cefmetazole in serious infection by Staphylococcus (author's transl)]. Jpn J Antibiot 1982; 35:821-34. [PMID: 6954289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Cefmetazole (CMZ) is an antibiotic agent belonging to the cephamycin group, which is resistant to beta-lactamase and has a broad antibacterial spectrum covering from Gram-negative to -positive organisms. Although this agent has been proved to have an antibacterial activity against Staphylococcus spp., it has not been used for treatment of the infections caused by the organism. Thus, 62 strains of S. aureus isolated clinically were compared for their sensitivity to CMZ, cefoxitin (CFX), cefuroxime (CXM), cefazolin (CEZ), and ampicillin (ABPC). In addition, 5 children suffering from septicemia due to S. aureus were treated with CMZ 158 mg/kg at a mean daily dose for a mean period of 14 days. The dose was used after dividing into 3 and 4 equal parts in 1 and 4 children, respectively. One old patient with septicemia was given 2,000 mg of CMZ twice daily for 4 days and once daily for subsequent 3 days. Another child with bacterial meningitis was treated with 50 mg/kg of CMZ 4 times daily for 63 days. The drug was given intravenous injection by one-shot or drip infusion in all cases under observation of clinical effects, bacteriological effects and side effects. The MIC of CMZ against S. aureus at inoculum sizes of 10(6) and 10(8) cells/ml was 1.56 mcg/ml in 72.6 and 56.5% of the strains, respectively. When 5 drugs were compared on the basis of the MIC to which the largest number of strains were sensitive, CEZ was most active, and CMZ was ranked in the next place and similar to CXM in activity. However, when the whole range of the MIC was considered, CMZ was more excellent than CXM, its MIC was lower than those of CEZ, CFX and ABPC in a greater number of strains. It was considered from the results that the serum level of CMZ was effective against 100 and 93.5% of strains at an inoculum size of 10(6) cells/ml and against 100 and 83.9% of strains at an inoculum size of 10(8) cells/ml until 4 and 6 hours after a one-shot intravenous injection of 50 mg/kg of Moni-trol I standard, respectively in the children. Thus, CMZ is expected to manifest a sufficient effect on septicemia caused by S. aureus in children who receive a one-shot intravenous injection of 50 mg/kg of it 4 times daily. Treatment with CMZ was clinically evaluated to be excellent in 3, good in 3 and poor in none of 6 patients with septicemia due to S. aureus, and fair in the 1 with Staphylococcal meningitis. The bacteriological result was excellent, since the causal organisms were eradicated in all cases. With regard to side effects, abnormal eosinophilia was found in 2 cases, but it was no ascribable to this drug in 1 of them. GOT showed an abnormal rise in 1 case and both GOT and GPT in 1, although they were considered not to be related to this drug in either case. It is considered from these results that CMZ is a valuable drug in treatment of septicemia due to S. aureus.
Collapse
|